CATALYSTYahoo Finance • 14h ago
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to BuyYahoo Finance report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
Why AUTL Stock dropped -3.80% Today — RQD Quant Desk Flash
$1.52 -3.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.51
Autolus Therapeutics plc (AUTL) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $420.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AUTL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AUTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Autolus Therapeutics plc (NASDAQ: AUTL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.52 (-3.80% 1D, market cap $420.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AUTL ranks #983 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AUTL compare to ALLO and CCCC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AUTL carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of -27.8%, and ROIC of -35.0%. By comparison, ALLO (Allogene Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M) and CCCC (C4 Therapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $406.0M). Among the 5-stock peer group, AUTL leads on earnings multiple (N/A) while AUTL leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AUTL?
▼
Per AUTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730463), Autolus Therapeutics plc generated $75.4M in revenue (+644.9% YoY), -$287.5M in net income, and -$302.6M in free cash flow against $589.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.51 (-0.87%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (21/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-16.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AUTL)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (21/100 Composite)
🔍 WHY AUTL SCORES 21/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+6/20 pts (29% of score)
FRED Regime × Technicals: 25% of 52W Range • RSI-14 at 41.7 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (24% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.74-8.6% Next Q
29
Q2 (-2Q)Grade E$1.59-3.8% Next Q
26
Q3 (-1Q)Grade E$1.53-0.7% Next Q
24
CurrentGrade E$1.52-11.6% Hist 90D α
21
Trajectory: E (29) → E (21)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AUTL Turnaround Squeeze
While AUTL currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.89) and Max Pain ($1.60) forces dealer call-delta covering toward $2.71.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AUTL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AUTL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AUTL Stock dropped -3.80% Today — RQD Quant Desk Flash
Autolus Therapeutics plc (AUTL) dropped -3.80% to $1.52, trading at 25% of its 52-week range ($1.17 – $2.58). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 25% of its 52-week range ($1.17 – $2.58) with RSI-14 at 41.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.6% around $1.52 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.
Live AUTL Headlines & Catalysts
MARKET WIRESeeking Alpha • 17h ago
Autolus Therapeutics: Key Questions For The Near TermSeeking Alpha report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 20h ago
Autolus Therapeutics plc Estimates – NASDAQ:AUTLTradingView report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 23h ago
Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst PredictionsSimply Wall St report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven (NASDAQ:AUTL)Seeking Alpha report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREkalkine.ca • 1d ago
Why Is Autolus Therapeutics (NASDAQ:AUTL) Down 10.92% Pre-Market, and Is More Selling Ahead?kalkine.ca report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 1d ago
H.C. Wainwright initiates Autolus stock coverage with buy rating By Investing.comInvesting.com India report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock NowYahoo Finance report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 22h ago
HC Wainwright & Co. Assumes Autolus Therapeutics at Buy, Announces Price Target of $10HC Wainwright & Co. analyst Douglas Tsao assumes Autolus Therapeutics (NASDAQ:AUTL) with a Buy rating and announces Price Target of $10.
MARKET WIREYahoo • 7d ago
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AUTL)
- ✓Walkthrough of AUTL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AUTL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.18%📐 HORIZONTAL RANGE
2026-11-02O $1.63H $1.63L $1.52C $1.52VOL 2.35M
RES: $3.09SUP: $1.38SMA50: $1.89SMA200: $1.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AUTL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AUTL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AUTL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AUTL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AUTL)
Health Care Rank #983 of 1016
⚔️ ALLO vs AUTL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AUTL vs. ALLO, CCCC, TECX, PROK)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Autolus Therapeutics plc (AUTL) ranks #983 by composite RQD confidence (21/100, grade E) and #473 by equity capitalization ($420.5M). Within this direct 5-issuer industry benchmark cohort, AUTL leads on earnings valuation at N/A trailing P/E, while AUTL leads on capital efficiency and profitability with -35.0% ROIC and -27.8% gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 37/100 (D-) compared with AUTL at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AUTL
ACTIVE
Autolus Therapeutics plc | E | 21/100 | — | -27.8% | -35.0% | -3.80% | $420.5M | Benchmark Subject |
| ALLO Allogene Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -5.60% | $431.9M | /allo-vs-autl → |
| CCCC C4 Therapeutics Inc. | E | 28/100 | — | — | -35.0% | +2.12% | $406.0M | /cccc-vs-autl → |
| TECX Tectonic Therapeutic Inc. | E | 30/100 | — | — | -35.0% | -3.51% | $400.8M | /tecx-vs-autl → |
| PROK ProKidney Corp. (Class A) | D- | 37/100 | — | — | -35.0% | -11.90% | $444.4M | /prok-vs-autl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001730463In its most recent audited fiscal period (FY2025, filed 2025-12-31), Autolus Therapeutics plc (AUTL) reported GAAP revenue of $75.4M (+644.9% vs. FY2024 revenue of $10.1M , and +4339.8% cumulative change since FY2023) , GAAP net income of -$287.5M, operating cash flow of -$283.6M, and free cash flow of -$302.6M (-32.5% YoY). On the balance sheet, AUTL closed FY2025 with $589.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $75.4M | -$287.5M | -$283.6M | -$302.6M | $589.1M | — |
| FY2024 (FY) | 2024-12-31 | $10.1M | -$220.7M | -$206.3M | -$228.3M | $782.7M | — |
| FY2023 (FY) | 2023-12-31 | $1.7M | -$208.4M | -$145.6M | -$145.6M | — | — |
3. AUTL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AUTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Autolus Therapeutics plc (NASDAQ: AUTL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.52 (-3.80% 1D, market cap $420.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, AUTL ranks #983 in composite RQD confidence.
How does AUTL compare to ALLO and CCCC in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AUTL carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of -27.8%, and ROIC of -35.0%. By comparison, ALLO (Allogene Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M) and CCCC (C4 Therapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $406.0M). Among the 5-stock peer group, AUTL leads on earnings multiple (N/A) while AUTL leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AUTL?
Per AUTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001730463), Autolus Therapeutics plc generated $75.4M in revenue (+644.9% YoY), -$287.5M in net income, and -$302.6M in free cash flow against $589.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AUTL trading relative to its 50-day, 200-day, and 52-week technical levels?
AUTL last traded at $1.52 (-3.80% on volume of 1,675,296 shares), positioning the stock -19.58% below its 50-day simple moving average ($1.89) and -8.98% below its 200-day simple moving average ($1.67). Across its 52-week range of $1.17 to $2.58, AUTL sits at the 24.8% percentile with a 14-day RSI of 41.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($1.34 to $1.70).
AUTL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AUTL stock moving today?
Why AUTL Stock dropped -3.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 21/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
AUTL — Autolus Therapeutics plc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:44Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, AUTL scores 21 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 3 / 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating returns on capital or free cash flow. The whale 13F flow pillar scores 4 / 20 (institutional accumulation and options positioning), suggesting weak institutional support in the rating's inputs. The insider conviction pillar scores 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), indicating little supportive insider signaling. The macro regime fit pillar scores 6 / 20 (Beta 1.0; sector sensitivity), a middling reading on market sensitivity. The forensic balance sheet pillar scores 5 / 20 (Altman Z 0.2; Piotroski F 3/9; Debt/Equity 0.5), the most direct signal of financial stress in the rating. For a prospective investor, the upside case depends on a turnaround in cash generation that the reported figures do not yet show, while the valuation tradeoff is that earnings-based multiples cannot be assessed from available data. Second-order risk is elevated because weak balance-sheet and cash-flow pillars can amplify sensitivity to any financing or operating setback. This is an analytical summary, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $75.4M | $-270.5M | $-287.5M | N/A | $-302.6M | $104.1M | N/A |
| FY 2024 | $10.1M | $-241.4M | $-220.7M | N/A | $-228.3M | $227.4M | N/A |
| FY 2023 | $1.7M | $-179.7M | $-208.4M | N/A | $-145.6M | N/A | N/A |
Per the SEC financials, revenue rose from $1.7M (FY 2023) to $10.1M (FY 2024) to $75.4M (FY 2025), while operating losses and net losses remained large in each period. Per the market data, gross margin is -27.8%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Reported cash declined from $227.4M (FY 2024) to $104.1M (FY 2025), and FY 2025 free cash flow was $-302.6M.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, six headlines are tagged to AUTL, all with a relative time within the past 15 hours. One item, a Yahoo Finance report, is labeled CATALYST and carries a GREEN light; it is titled "All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy." The remaining five items are labeled MARKET WIRE with YELLOW lights, including a Seeking Alpha piece titled "Autolus Therapeutics: Key Questions For The Near Term" and a kalkine.ca piece titled "Why Is Autolus Therapeutics (NASDAQ:AUTL) Down 10.92% Pre-Market, and Is More Selling Ahead?" Risk watch items include the Seeking Alpha headline "Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven." Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What are Autolus's reported product lines and customer base, and what drives the revenue increase from $1.7M to $75.4M across FY 2023–FY 2025?
- What is the company's debt position, since the debt field is N/A for all reported periods?
- What is the basis for the "Rating Upgrade to Buy" headline, and which analyst or source issued it?
- What is the company's cash runway given cash of $104.1M against FY 2025 free cash flow of $-302.6M?
- What EPS and P/E figures would apply, since EPS and valuation multiples are not available in the source data?
AUTL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Autolus Therapeutics plc (AUTL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 14h ago
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy Yahoo Finance report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 17h ago
Autolus Therapeutics: Key Questions For The Near Term Seeking Alpha report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 20h ago
Autolus Therapeutics plc Estimates – NASDAQ:AUTL TradingView report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 23h ago
Autolus Therapeutics (NasdaqGS:AUTL) Stock Forecast & Analyst Predictions Simply Wall St report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven (NASDAQ:AUTL) Seeking Alpha report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE kalkine.ca • 1d ago
Why Is Autolus Therapeutics (NASDAQ:AUTL) Down 10.92% Pre-Market, and Is More Selling Ahead? kalkine.ca report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 1d ago
H.C. Wainwright initiates Autolus stock coverage with buy rating By Investing.com Investing.com India report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now Yahoo Finance report covering Autolus Therapeutics plc (AUTL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AUTL Bull vs. Bear Conversation Board — What's Your Call at $1.52?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AUTL 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.39 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is AUTL (E • RQD 21/100) a Buy at $1.58?
Welcome to the AUTL (Autolus Therapeutics plc) Roar Pit. Current RQD Composite is 21/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.20 (-24.1%)
Spot @ $1.58 Pump the brakes on AUTL — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on AUTL, but look at what you are paying: current EV/EBITDA multiples with -27.8% gross margins. Unless Autolus Therapeutics plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.85 (+17.1%)
Spot @ $1.58 AUTL cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on AUTL, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.58 (52-wk range $1.17 - $2.58), any beat on forward guidance forces shorts and underweight funds to chase.